

REVACLEAR 300/400/500 DIALYZER

OPTIMIZING HIGH FLUX PERFORMANCE

The **Revaclear** dialyzer series is a range of high flux dialyzers designed to optimize clearance with a smaller surface area!¹

SAFETY AND EFFICIENCY IN MIND

The relatively compact surface area and uniform flow characteristics of the **Revaclear** dialyzer may help meet clinical and operational objectives.

- Minimizes stagnant areas of blood, potentially reducing clotting.¹
- Provides easy and complete rinseback of blood after treatments.¹

MAY REDUCE NEED FOR SALINE

The **Revaclear** dialyzer does not require saline to be discarded and refilled after recirculation.^{2-4*}

MAY LEAD TO AN ESTIMATED SAVINGS OF \$660 PER PATIENT ANNUALLY THROUGH REDUCED ESA USAGE

In a large-scale, retrospective, observational study of US HD patients (N ~37,500), the **Revaclear 300** and **400** dialyzers were associated with lower doses of Erythropoiesis-Stimulating Agents used per session compared with **Optiflux** dialyzers.⁵ The median difference was 275 fewer units of ESAs, which could lead to \$4.39 in savings per treatment.⁶⁻⁸



*After priming the dialysate compartment the fluid in the blood compartment may contain bicarbonate. During patient connection the volume and rate of infusion of this fluid needs to be considered. Especially for patients with metabolic acidosis, discard as much as possible of the priming solution.

The images are for illustration purposes only and may differ from the actual product.

REVACLEAR SPECIFICATIONS

MATERIALS	REVACLEAR 300	REVACLEAR 400	REVACLEAR 500
Membrane	Poracton Polyarylethersulfone and Polyvinylpyrrolidone blend BPA-free		
Potting	Polyurethane (PUR)		
Housing	Polycarbonate (PC)		
Gaskets	Silicone rubber (SIR)		
Protection caps	Polypropylene (PP)		
Sterilization	Steam (inside-out)		
Sterile barrier	Tyvek		
SPECIFICATIONS			
UF-Coefficient (mL/h*mmHg)*	48	54	65
KoA urea*	1186	1439	1578
Blood Compartment volume (mL)	74	93	106
Minimum recommended priming volume (mL)	300		
Maximum TMP (mmHg)	600		
Recommended Q _B (mL/min)	200-500	200-600	250-600
Storage conditions	≤ 30°C / 86°F		
Units per box	24		
Gross/net weight (g)	215/160	225/170	250/190
MEMBRANE			
Membrane Area (m ²)	1.4	1.8	2.1
Fiber inner diameter (µm)	190		
Fiber wall thickness (µm)	35		
ORDERING			
Product Code	114745L	114746L	955543A

CLEARANCES IN VITRO (mL/min)*	REVACLEAR 300	REVACLEAR 400	REVACLEAR 500
Urea (60 Da) (Q_B-Q₀, mL/min)			
200-250**/500	196	198	244
300/500	272	281	284
400/500	323	338	345
400/800	355	369	375
500/800	408	430	439
Creatinine (113 Da)			
200-250**/500	191	195	238
300/500	256	267	272
400/500	298	315	323
400/800	330	348	355
500/800	373	398	409
Phosphate (142 Da)			
200-250**/500	185	191	230
300/500	242	255	261
400/500	278	297	306
400/800	309	330	338
500/800	345	373	384
Vitamin B12 (1.4 kDa)			
200-250**/500	146	158	183
300/500	174	191	200
400/500	191	213	223
400/800	212	236	247
500/800	228	256	269
SIEVING COEFFICIENTS*			
Vitamin B12 (1,4 kDa)		1.0	
Inulin (5,2 kDa)		1.0	
β ₂ -microglobulin (11,8 kDa)		0.95	
Myoglobin (17 kDa)		0.68	
Albumin (66,4 kDa)		0.0027	

* According to ISO 8637-1

- UF-Coefficient: measured with bovine blood, Hct 32%, Pct 60g/L, 37°C

- KoA urea: calculated at Q_B=300 mL/min, Q₀=500mL/min, UF=0 mL/min

- Sieving coefficients for Vitamin B12 and Inulin measured with bovine plasma, Q_B=500 mL/min, UF=100 mL/min

- Sieving coefficients for β₂-microglobulin, Myoglobin, and Albumin measured with human plasma, Q_B=300 mL/min, UF=60 mL/min

- Clearances In-Vitro: measured at UF=0 mL/min, ±10%

** REVACLEAR 500

Revaclear 300, 400, and 500 dialyzers are indicated for treatment of chronic or acute renal failure.

For single use only.

Rx Only. For safe and proper use of the device, please refer to the Instructions for Use.

1. REVACLEAR White Paper. REVACLEAR dialyzers: Optimized for efficient high-flux HD treatments, May 2013. Baxter Healthcare Corporation.
2. REVACLEAR 300 400 IFU, 2019.
3. Revaclear 300 400 500 IFU, 2022.
4. OPTIFLUX F160NR F180NR F200NR F250NR IFU, 2016.
5. Sibbel S, Hunt A, Laplante S, Beck W, Gellens M, Brunelli SM. Comparative effectiveness of dialyzers: a longitudinal, propensity score-matched study of incident hemodialysis patients. ASAIO journal. Jul 20 2016.
6. Baxter data on file. Final Study Report, December 2014.
7. EPOGEN (Epoetin alfa) RED BOOK Online Product Details. Micromedex Solutions. 2016.
8. Baxter data on file. Cost Calculation. Assumes 150 dialysis sessions per patient per year.

renalcareus.baxter.com/revaclear

Baxter Healthcare Corporation

One Baxter Parkway

Deerfield, IL 60015

USA

1-800-422-9837

Baxter, Poracton and Revaclear are trademarks of Baxter International Inc. or its subsidiaries.

Optiflux is a trademark of Fresenius Medical Care Holdings, Inc. or its affiliated companies

US-RC38-230001 v2.0 05/23